Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 14, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the...
View HTML
Toggle Summary Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on...
View HTML
Toggle Summary Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam
Company’s Resources Focused on Advancement of All Key Pipeline Programs CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- Dicerna Pharmaceuticals, Inc . (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has...
View HTML
Toggle Summary Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a...
View HTML
Toggle Summary Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a corporate overview at...
View HTML
Toggle Summary Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter...
View HTML
Toggle Summary Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Cowen and Company...
View HTML
Toggle Summary Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2017 financial results after market close on...
View HTML
Toggle Summary Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in two investor...
View HTML
Toggle Summary Dicerna to Present at Noble Capital Markets' NobleCon14
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at NobleCon14 - Noble...
View HTML